Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA.
Clin Cancer Res. 2013 Jul 15;19(14):3936-43. doi: 10.1158/1078-0432.CCR-13-0895. Epub 2013 Jun 6.
Immune-related response criteria (irRC) was developed to adequately assess tumor response to immunotherapy. The irRC are based on bidimensional measurements, as opposed to unidimensional measurements defined by Response Evaluation Criteria in Solid Tumors, which has been widely used in solid tumors. We aimed to compare response assessment by bidimensional versus unidimensional irRC in patients with advanced melanoma treated with ipilimumab.
Fifty-seven patients with advanced melanoma treated with ipilimumab in a phase II, expanded access trial were studied. Bidimensional tumor measurement records prospectively conducted during the trial were reviewed to generate a second set of measurements using unidimensional, longest diameter measurements. The percent changes of measurements at follow-up, best overall response, and time-to-progression (TTP) were compared between bidimensional and unidimensional irRC. Interobserver variability for bidimensional and unidimensional measurements was assessed in 25 randomly selected patients.
The percent changes at follow-up scans were highly concordant between the 2 criteria (Spearman r: 0.953-0.965, first to fourth follow-up). The best immune-related response was highly concordant between the 2 criteria (κw = 0.881). TTP was similar between the bidimensional and unidimensional assessments (progression-free at 6 months: 70% vs. 81%, respectively). The unidimensional measurements were more reproducible than bidimensional measurements, with the 95% limits of agreement of (-16.1%, 5.8%) versus (-31.3%, 19.7%), respectively.
irRC using the unidimensional measurements provided highly concordant response assessment compared with the bidimensional irRC, with less measurement variability. The use of unidimensional irRC is proposed to assess response to immunotherapy in solid tumors, given its simplicity, higher reproducibility, and high concordance with the bidimensional irRC.
免疫相关缓解标准(irRC)是为了充分评估免疫疗法对肿瘤的疗效而制定的。irRC 基于二维测量,而不是实体瘤反应评估标准中定义的一维测量,后者已广泛用于实体瘤。我们旨在比较使用二维和一维 irRC 评估接受伊匹单抗治疗的晚期黑色素瘤患者的缓解情况。
对一项 II 期扩大准入试验中接受伊匹单抗治疗的 57 例晚期黑色素瘤患者进行研究。回顾性地审查试验期间进行的前瞻性二维肿瘤测量记录,使用一维最长直径测量生成第二组测量结果。比较二维和一维 irRC 之间的测量值在随访时的百分比变化、最佳总体缓解和无进展生存期(TTP)。在 25 例随机选择的患者中评估了二维和一维测量的观察者间变异性。
两种标准之间的随访扫描时的百分比变化高度一致(Spearman r:0.953-0.965,首次至第四次随访)。两种标准之间的最佳免疫相关缓解高度一致(κw = 0.881)。TTP 在二维和一维评估之间相似(无进展生存期 6 个月:分别为 70%和 81%)。一维测量比二维测量更具可重复性,其 95%一致性界限分别为(-16.1%,5.8%)和(-31.3%,19.7%)。
与二维 irRC 相比,使用一维测量的 irRC 提供了高度一致的缓解评估,且具有更少的测量变异性。鉴于其简单性、更高的可重复性以及与二维 irRC 的高度一致性,建议在实体瘤中使用一维 irRC 来评估免疫治疗的疗效。